title: What's new in …. HIV/AIDS treatment IRIS complicates recovery of immune status.
authors.affiliation: The authors work at the College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City. Daniel O'Donoghue is a professor in the Department of Family and Preventive Medicine. Tara Gleaves works in the Department of Internal Medicine, Section of Infectious Diseases. Michelle Salvaggio is Assistant Professor, Department of Internal Medicine, Section of Infectious Diseases. All have indicated no relationships to disclose relating to the content of this article.
authors.forename: Daniel L
authors.initials: DL
authors.lastname: OʼDonoghue
authors.forename: Tara
authors.initials: T
authors.lastname: Gleaves
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Salvaggio
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D003453:Cryptococcosis / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000276:immunology; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced* / Q000276:immunology* / Q000628:therapy; D015270:Mycobacterium avium-intracellulare Infection / Q000276:immunology
chemical_list: D019380:Anti-HIV Agents